
## Scott McCallister

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3610071/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet, The, 2020, 396, 239-254.	13.7	245
2	Tenofovir Alafenamide for HIV Preexposure Prophylaxis. Annals of Internal Medicine, 2020, 173, 77-78.	3.9	1
3	Estimation of new HIV diagnosis rates among highâ€risk, PrEPâ€eligible individuals using HIV surveillance data at the Metropolitan Statistical Area level in the United States. Journal of the International AIDS Society, 2019, 22, e25433.	3.0	10
4	Plasma concentration of neurofilament light chain protein decreases after switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate. PLoS ONE, 2019, 14, e0226276.	2.5	14
5	Title is missing!. , 2019, 14, e0226276.		0
6	Title is missing!. , 2019, 14, e0226276.		0
7	Title is missing!. , 2019, 14, e0226276.		0
8	Title is missing!. , 2019, 14, e0226276.		0
9	Superior Efficacy and Improved Renal and Bone Safety After Switching from a Tenofovir Disoproxil Fumarate- to a Tenofovir Alafenamide-Based Regimen Through 96 Weeks of Treatment. AIDS Research and Human Retroviruses, 2018, 34, 337-342.	1.1	74
10	Brief Report: Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment: Week 144 Results. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 75, 211-218.	2.1	102
11	A Randomized, Open-Label Trial to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Darunavir in Treatment-Experienced HIV-1-Infected Adults. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 74, 193-200.	2.1	45
12	Equivalent Decline in Inflammation Markers with Tenofovir Disoproxil Fumarate vs. Tenofovir Alafenamide. EBioMedicine, 2016, 13, 321-327.	6.1	16
13	Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B–Coinfected Adults. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 73, 294-298.	2.1	55
14	Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study. Lancet Infectious Diseases, The, 2016, 16, 43-52.	9.1	256
15	Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet, The, 2015, 385, 2606-2615.	13.7	521